TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7934974

Group type: EXPERIMENTAL
Intervention: Insulin therapy (continuous intravenous infusion)
Number of subjects: 19
Study: 2456735

Group type: EXPERIMENTAL
Intervention: 1% silver nitrate
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 1% tetracycline
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group (forgotten babies)
Number of subjects: 450
Study: 30328936

Group type: EXPERIMENTAL
Intervention: Critical Load (CL)
Number of subjects: 12
Study: 29146648

Group type: EXPERIMENTAL
Intervention: E-PsEYE e-mental health intervention based on cognitive-behavioral therapy (CBT) with nine modules delivered in a stepped-care model.
Number of subjects: 174

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 174
Study: 26592061

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (12 weekly messages)
Number of subjects: 158
Study: 23440247

Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 µg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FF/VI 200/25 µg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 500 µg twice daily
Number of subjects: 0
Study: 21309841

Group type: EXPERIMENTAL
Intervention: Electronic feedback system to general practitioners
Number of subjects: 2458

Group type: COMPARATOR
Intervention: Control group (no electronic feedback)
Number of subjects: 2458
Study: 18958384

Group type: EXPERIMENTAL
Intervention: Exercise + fortified milk
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fortified milk
Number of subjects: 180

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 180
Study: 16704995

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 113

Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 113
Study: 15224654

Group type: EXPERIMENTAL
Intervention: Intra-uterine system releasing 10 micrograms/day levonorgestrel and 2 mg oral estradiol (trial 1)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intrauterine system releasing 20 micrograms/day levonorgestrel and 2 mg estradiol (trial 2)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combination of 1 mg norethisterone acetate and 2 mg estradiol (trial 2)
Number of subjects: 94
Study: 11218416

Group type: EXPERIMENTAL
Intervention: Cochrane Collaboration involvement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cochrane Collaboration and EBM recognition
Number of subjects: 0
Study: 9203809

Group type: EXPERIMENTAL
Intervention: Imidazole salycilate (IS) 1,500 mg acute dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Imidazole salycilate (IS) 750 mg t.i.d. for 15 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Imidazole salycilate (IS) 750 mg t.i.d. for 30 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7951791

Group type: EXPERIMENTAL
Intervention: Multidisciplinary model including clinical and ergonomic interventions
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ergonomic and clinical interventions
Number of subjects: 79
Study: 2735733

Group type: EXPERIMENTAL
Intervention: 60 mg per day of trimetazidine (TMZ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 20
Study: 30674586

Group type: EXPERIMENTAL
Intervention: Inhaled lipopolysaccharide (LPS) 50 µg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Inhaled saline
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Patients with COPD
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Repeat radiolabelling/imaging in COPD patients
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: LPS challenge
Number of subjects: 38
Study: 28403554

Group type: EXPERIMENTAL
Intervention: Continuous veno‐venous hemofiltration (CVVH)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Slow continuous ultrafiltration (SCUF)
Number of subjects: 120
Study: 26136484

Group type: EXPERIMENTAL
Intervention: Video ON
Number of subjects: 3017

Group type: COMPARATOR
Intervention: Video OFF
Number of subjects: 3017

Group type: EXPERIMENTAL
Intervention: Self-initiated video viewing
Number of subjects: 3017

Group type: EXPERIMENTAL
Intervention: Automated video viewing
Number of subjects: 3017
Study: 23387398

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 120
Study: 21693044

Group type: EXPERIMENTAL
Intervention: Hand therapy with night-splinting
Number of subjects: 154

Group type: COMPARATOR
Intervention: Hand therapy only
Number of subjects: 154
Study: 18516681

Group type: EXPERIMENTAL
Intervention: Communities That Care prevention operating system
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 24
Study: 16456637

Group type: EXPERIMENTAL
Intervention: 0.2 percent glycerine trinitrate ointment applied three times daily at the anal margin for eight weeks (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 units Botulinum toxin A injection into the internal anal sphincter on each side of the anterior midline (Group B)
Number of subjects: 30
Study: 15383188

Group type: EXPERIMENTAL
Intervention: Orlistat plus hypocaloric diet (HCD)
Number of subjects: 126

Group type: COMPARATOR
Intervention: HCD alone
Number of subjects: 126
Study: 11146152

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (Utrecht Octopus Method)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Repeat angiography at 1 year
Number of subjects: 560
Study: 8618654

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 2000000
Study: 1634914

Group type: COMPARATOR
Intervention: LOPP
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: LOPP/EVAP
Number of subjects: 594
Study: 6373644

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 103

Group type: COMPARATOR
Intervention: No-surgery group
Number of subjects: 103
Study: 30109585

Group type: EXPERIMENTAL
Intervention: Transition Services (TS) program (n = 935)
Number of subjects: 1876

Group type: COMPARATOR
Intervention: Usual care (n = 941)
Number of subjects: 1876
Study: 28777245

Group type: EXPERIMENTAL
Intervention: Energy Shot (ES)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 25635420

Group type: EXPERIMENTAL
Intervention: 4 mg intrathecal hyperbaric bupivacaine with 2.5 μg sufentanil
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 6 mg intrathecal hyperbaric bupivacaine with 2.5 μg sufentanil
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 8 mg intrathecal hyperbaric bupivacaine with 2.5 μg sufentanil
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 10 mg intrathecal hyperbaric bupivacaine with 2.5 μg sufentanil
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ED 50 of intrathecal bupivacaine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ED 95 of intrathecal bupivacaine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Overall satisfaction and newborns' Apgar score
Number of subjects: 200
Study: 24996507

Group type: EXPERIMENTAL
Intervention: ω‐3 PUFAs (eicosapentaenoic acid 2g/day and docosahexaenoic acid 1g/day) + α‐LA 300 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 21848460

Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia
Number of subjects: 6041

Group type: COMPARATOR
Intervention: ETAC-guided anesthesia
Number of subjects: 6041
Study: 18414504

Group type: EXPERIMENTAL
Intervention: Serum carotenoid concentrations measured in participants over 4 years
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Lycopene measurement
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Lutein/zeaxanthin and beta-carotene measurements
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Center and center-by-season effects
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Blood measurements
Number of subjects: 1905
Study: 17209178

Group type: EXPERIMENTAL
Intervention: High-glycemic load meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-glycemic load meal
Number of subjects: 16
Study: 15179406

Group type: EXPERIMENTAL
Intervention: ABT-773 450 mg in CYP3A5-negative subjects (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: ABT-773 450 mg in CYP3A5-positive subjects (n = 8)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ABT-773 150 mg or 300 mg
Number of subjects: 17
Study: 11455374

Group type: EXPERIMENTAL
Intervention: Antimicrobial varnish in combination with fluoride varnish (group 1)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Fluoride varnish alone (group 2)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Combination of antimicrobial and fluoride varnishes
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Antimicrobial varnish
Number of subjects: 220
Study: 9543133

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day, n = 16)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Toremifene (40 mg/day, n = 14)
Number of subjects: 30
Study: 8053353

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viloxazine
Number of subjects: 0
Study: 2726331

Group type: EXPERIMENTAL
Intervention: Schedule A (10 micrograms of hepatitis B vaccine at 0, 1, 2, and 11 months)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Schedule B (10 micrograms of hepatitis B vaccine at 3, 4, 5, and 11 months)
Number of subjects: 180
Study: 30885407

Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Posterolateral Approach (PA)
Number of subjects: 87
Study: 29017589

Group type: EXPERIMENTAL
Intervention: Combined intervention (telephone and in-person)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: In-person intervention
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 26471805

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Cobalt-chromium everolimus-eluting stents (CoCr-EES)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 480

Group type: COMPARATOR
Intervention: CoCr-EES
Number of subjects: 480
Study: 23530695

Group type: EXPERIMENTAL
Intervention: Student before Doctor
Number of subjects: 151

Group type: COMPARATOR
Intervention: No Student
Number of subjects: 151

Group type: COMPARATOR
Intervention: Student with Doctor
Number of subjects: 151
Study: 21592131

Group type: EXPERIMENTAL
Intervention: Scheduled school nurse inspections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group reporting to NMDOH only
Number of subjects: 0
Study: 19547639

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation
Number of subjects: 152
Study: 16686562

Group type: EXPERIMENTAL
Intervention: Plyometrics (PLYO)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Dynamic stabilization and balance training (BAL)
Number of subjects: 19
Study: 14608552

Group type: EXPERIMENTAL
Intervention: Conversation and assertive skills training (8 group training sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine nursing care treatment (control group)
Number of subjects: 0
Study: 10999966

Group type: EXPERIMENTAL
Intervention: Lined appliance
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unlined appliance
Number of subjects: 19
Study: 8960720

Group type: EXPERIMENTAL
Intervention: 3,4-DL-threo-dihydroxyphenylserine (DL-DOPS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1578079

Group type: EXPERIMENTAL
Intervention: UV‐A condition (light therapy with UV-A wavelengths)
Number of subjects: 33

Group type: COMPARATOR
Intervention: UV-blocked condition (light therapy without UV-A wavelengths)
Number of subjects: 33
Study: 3933645

Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulses followed by low dose oral prednisone for six months
Number of subjects: 89

Group type: COMPARATOR
Intervention: High dose oral prednisone for four weeks followed by low dose oral prednisone for five months
Number of subjects: 89
Study: 31071660

Group type: EXPERIMENTAL
Intervention: Zoned high compression shorts (ZHC‐shorts)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non‐zoned low compression shorts (NZLC‐shorts)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal sports clothes
Number of subjects: 34
Study: 29795470

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion with duodenal switch (BPD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BPD and RYGB (combined)
Number of subjects: 20
Study: 27531286

Group type: EXPERIMENTAL
Intervention: Bromfenac ophthalmic solution 0.09%
Number of subjects: 62

Group type: COMPARATOR
Intervention: Topical steroid (dexamethasone 0.1% and tobramycin 0.3%) alone
Number of subjects: 62
Study: 24485397

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 0
Study: 22335395

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention consisting of self‐monitored blood pressure, medicine review, a Digital Versatile Disc, and motivational interviewing telephone calls over 3 months.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 75
Study: 20003697

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF) 400 mg daily for the first 2 months
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Standard regimen plus daily 400 mg MXF
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard regimen alone (HERZ group)
Number of subjects: 150
Study: 18568239

Group type: EXPERIMENTAL
Intervention: Urologist with 25 TURP procedures (Group I - 24 patients)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Urologist with 50 TURP procedures (Group II - 24 patients)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Senior urologist with vast experience (Group III - 19 patients)
Number of subjects: 67

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 67
Study: 16652032

Group type: EXPERIMENTAL
Intervention: Didanosine and stavudine
Number of subjects: 329

Group type: COMPARATOR
Intervention: Zidovudine and lamivudine plus efavirenz, nelfinavir, or both
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 329
Study: 12816895

Group type: EXPERIMENTAL
Intervention: Face perception
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face recognition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face repetition
Number of subjects: 0
Study: 10633648

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise program
Number of subjects: 11
Study: 7477192

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (t‐PA)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 2318945

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Arginine
Number of subjects: 18
Study: 373124

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Indomethacin (after switching from placebo)
Number of subjects: 32
Study: 30607782

Group type: EXPERIMENTAL
Intervention: Omega-3 long chain polyunsaturated fatty acids (722 mg docosahexaenoic acid)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 IU daily)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both Vitamin D and Omega-3 (VIDOM)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 28182797

Group type: EXPERIMENTAL
Intervention: Real-time visual feedback during gait retraining
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (uninjured individuals)
Number of subjects: 16
Study: 25443863

Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) - single session
Number of subjects: 28

Group type: COMPARATOR
Intervention: Transarterial chemoembolization (TACE) - mean of 3.4 (median 2) interventions
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both SIRT and TACE
Number of subjects: 28
Study: 23379593

Group type: EXPERIMENTAL
Intervention: Education program based on the Knowledge Enhances Your Safety (KEYS) program, adapted for the Australian context.
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 380
Study: 21150467

Group type: EXPERIMENTAL
Intervention: Irinotecan (50 mg/m on days 1, 8, and 15) plus paclitaxel (180 mg/m on day 1) every 4 weeks (IP group)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Irinotecan (100 mg/m on days 1 and 8) plus gemcitabine (1000 mg/m on days 1 and 8) every 3 weeks (IG group)
Number of subjects: 78
Study: 18999908

Group type: EXPERIMENTAL
Intervention: Patient messaging
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Physician messaging only (Control)
Number of subjects: 100000
Study: 16720743

Group type: EXPERIMENTAL
Intervention: Multidisciplinary interventions in the community
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12740043

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 1926

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1926
Study: 11435187

Group type: EXPERIMENTAL
Intervention: Interview version of the SF-12
Number of subjects: 106

Group type: COMPARATOR
Intervention: Questionnaire version of the SF-12
Number of subjects: 106
Study: 9557177

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training program (Group A, n = 20), 4 months duration
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training program (Group A, n = 20)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (Group B, n = 15)
Number of subjects: 35
Study: 8011965

Group type: EXPERIMENTAL
Intervention: Exodol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dolac
Number of subjects: 12
Study: 2595103

Group type: EXPERIMENTAL
Intervention: NaHCO3 (300 mg/kg body weight)
Number of subjects: 7

Group type: COMPARATOR
Intervention: CaCO3 (300 mg/kg body weight)
Number of subjects: 7
Study: 4933388

Group type: EXPERIMENTAL
Intervention: DEAE Sephadex (12‐15 g/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofibrate + DEAE Sephadex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clofibrate + Cholestyramine
Number of subjects: 0
Study: 7192075

Group type: EXPERIMENTAL
Intervention: Double-blind food challenge in children suspected of being allergic to egg or milk (40 children tested)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Children suspected of being allergic to egg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Children with both a present history of food allergy and a positive skin test for that allergen
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Positive challenges
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Diagnosis of food allergy in children sensitive to food allergens
Number of subjects: 126
Study: 31610633

Group type: EXPERIMENTAL
Intervention: Chronic cough
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Rhinitis
Number of subjects: 1000
Study: 28444936

Group type: EXPERIMENTAL
Intervention: HI‐ECC+BFR
Number of subjects: 9

Group type: COMPARATOR
Intervention: HI‐ECC
Number of subjects: 9
Study: 27376594

Group type: EXPERIMENTAL
Intervention: Community cash transfers (generasi)
Number of subjects: 26000

Group type: EXPERIMENTAL
Intervention: Household cash transfers (PKH)
Number of subjects: 26000
Study: 24411134

Group type: EXPERIMENTAL
Intervention: AAV2-NGF (CERE-110)
Number of subjects: 10
Study: 23495555

Group type: EXPERIMENTAL
Intervention: Chinpoint guidance
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Leaf gauge
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study: 20810509

Group type: EXPERIMENTAL
Intervention: IA‐BoNT/A
Number of subjects: 49

Group type: COMPARATOR
Intervention: IA‐placebo
Number of subjects: 49
Study: 17202154

Group type: EXPERIMENTAL
Intervention: Low physical activity levels
Number of subjects: 19574

Group type: EXPERIMENTAL
Intervention: Self-reported health measures
Number of subjects: 19574
Study: 16034308

Group type: EXPERIMENTAL
Intervention: DTIC plus nIFN‐alpha
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BOLD plus nIFN‐alpha
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: DTIC plus rIFN‐alpha2b
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: BOLD plus rIFN‐alpha2b
Number of subjects: 108

Group type: COMPARATOR
Intervention: BOLD
Number of subjects: 108

Group type: COMPARATOR
Intervention: All arms
Number of subjects: 108
Study: 12063096

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs) cited in guidelines
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: References of guidelines
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Guidelines with <2 RCTs cited
Number of subjects: 191
Study: 9866536

Group type: EXPERIMENTAL
Intervention: Blood sampling from peripheral intravenous infusion lines
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Peripheral saline locks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Peripheral venipuncture
Number of subjects: 55
Study: 7715904

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron i.v. + placebo p.o. before chemotherapy + 8 mg ondansetron p.o. b.d. until day 5
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Placebo i.v. + 8 mg ondansetron p.o. before chemotherapy + 8 mg ondansetron p.o. b.d. until day 5
Number of subjects: 488

Group type: COMPARATOR
Intervention: 3 mg granisetron i.v. + placebo p.o. before chemotherapy + placebo p.o. b.d. until day 5
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: i.v. and p.o. ondansetron
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: all-p.o. ondansetron regimen
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: i.v. + ondansetron group
Number of subjects: 488
Study: 2462067

Group type: EXPERIMENTAL
Intervention: Luteinizing hormone‐releasing hormone agonist buserelin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antiandrogen cyproterone acetate
Number of subjects: 12
Study: 880971

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg b.i.d. for 3 weeks and 200 mg b.i.d. for 3 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (6 weeks)
Number of subjects: 10